Akero Therapeutics, Inc. AKRO announced a statistically significant histological improvement in the primary endpoint of its mid-stage study, evaluating the efficacy and safety of efruxifermin (EFX) in ...
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...
So what does it take for a master perfumer to develop distinctive and classic scents? Yahoo Life Shopping delves into his thoughts, from ideation to getting his perfumes on the shelves. We also asked ...
Hosted on MSN
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Akero Therapeutics, Inc. (AKRO) closed the last trading session at $48.12, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Akero Therapeutics, Inc. (AKRO) is a stock that can certainly ...
On Monday, Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate ...
) has been revised to $64.26 / share. This is a decrease of 15.18% from the prior estimate of $75.76 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akero Therapeutics, Inc. (AKRO) one of those stocks right now? By taking a look ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results